Longer median overall survival and progression-free survival seen with erdafitinib versus chemotherapy<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Oct. 23, 2023 (HealthDay News) — For patients with metastatic urothelial carcinoma and\u00a0FGFR<\/em>\u00a0alterations with progression after previous treatment with anti-programmed cell death protein 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agents, erdafitinib results in significantly longer overall survival, according to a study published online Oct. 21 in the\u00a0New England Journal of Medicine<\/em>. The research was published to coincide with the annual meeting of the European Society for Medical Oncology, held from Oct. 20 to 24 in Madrid.<\/p>\n Yohann Loriot, M.D., Ph.D., from Universit \u00a9 Paris-Saclay, and colleagues conducted a global phase 3 trial of erdafitinib compared to chemotherapy in patients with metastatic urothelial carcinoma with susceptible\u00a0FGFR3\/2<\/em>\u00a0alterations who had progression after one or two previous treatments that included a PD-1 or PD-L1 agent. Patients were randomly assigned to erdafitinib or the investigator’s choice of chemotherapy (docetaxel or vinflunine; 136 and 130 patients, respectively) and were followed for a median of 15.9 months.<\/p>\n The researchers found that the median overall survival was significantly longer with erdafitinib than chemotherapy (12.1 versus 7.8 months; hazard ratio for death, 0.64), as was median progression-free survival (5.6 versus 2.7 months; hazard ratio for progression or death, 0.58). The two groups had a similar incidence of grade 3 or 4 treatment-related adverse events (45.9 and 46.4 percent, respectively). Treatment-related adverse events that led to death occurred less often with erdafitinib versus chemotherapy (0.7 versus 5.4 percent of patients).<\/p>\n “The overall survival benefit of erdafitinib in patients with metastatic urothelial carcinoma with\u00a0FGFR\u00a0<\/em>alterations supports molecular testing for\u00a0FGFR<\/em>\u00a0alterations in patients with metastatic urothelial cancer,” the authors write.<\/p>\n The study was funded by Janssen, the manufacturer of erdafitinib.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/ins><\/p>\n